Comprehension of confidence intervals - development and piloting of patient information materials for people with multiple sclerosis: qualitative study and pilot randomised controlled trial by unknown
RESEARCH ARTICLE Open Access
Comprehension of confidence intervals -
development and piloting of patient
information materials for people with
multiple sclerosis: qualitative study and
pilot randomised controlled trial
Anne C. Rahn1,2*, Imke Backhus1, Franz Fuest2, Karin Riemann-Lorenz3, Sascha Köpke3, Adrianus van de Roemer4,
Ingrid Mühlhauser2 and Christoph Heesen1
Abstract
Background: Presentation of confidence intervals alongside information about treatment effects can support
informed treatment choices in people with multiple sclerosis.
We aimed to develop and pilot-test different written patient information materials explaining confidence intervals
in people with relapsing-remitting multiple sclerosis. Further, a questionnaire on comprehension of confidence
intervals was developed and piloted.
Methods: We developed different patient information versions aiming to explain confidence intervals. We used an
illustrative example to test three different approaches: (1) short version, (2) “average weight” version and (3) “worm
prophylaxis” version. Interviews were conducted using think-aloud and teach-back approaches to test feasibility and
analysed using qualitative content analysis. To assess comprehension of confidence intervals, a six-item multiple
choice questionnaire was developed and tested in a pilot randomised controlled trial using the online survey
software UNIPARK. Here, the average weight version (intervention group) was tested against a standard patient
information version on confidence intervals (control group). People with multiple sclerosis were invited to take part
using existing mailing-lists of people with multiple sclerosis in Germany and were randomised using the UNIPARK
algorithm. Participants were blinded towards group allocation. Primary endpoint was comprehension of confidence
intervals, assessed with the six-item multiple choice questionnaire with six points representing perfect knowledge.
Results: Feasibility of the patient information versions was tested with 16 people with multiple sclerosis. For the
pilot randomised controlled trial, 64 people with multiple sclerosis were randomised (intervention group: n = 36;
control group: n = 28). More questions were answered correctly in the intervention group compared to the control
group (mean 4.8 vs 3.8, mean difference 1.1 (95 % CI 0.42–1.69), p = 0.002). The questionnaire’s internal consistency
was moderate (Cronbach's alpha = 0.56).
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Conclusions: The pilot-phase shows promising results concerning acceptability and feasibility. Pilot randomised
controlled trial results indicate that the patient information is well understood and that knowledge gain on confidence
intervals can be assessed with a set of six questions.
Trial registration: German Clinical Trials Register: DRKS00008561. Registered 8th of June 2015.
Keywords: Patient information, Multiple sclerosis, Confidence interval, Interview, Pilot randomised controlled trial
Background
Without knowledge and correct interpretation of numer-
ical information, informed decision-making is impeded.
The way statistical information is presented and explained
has a high impact on understanding and interpretation
[1]. In addition to information on absolute and relative
risk reduction, thoughtfully developed information on
confidence intervals (CI) for comparing treatment effects
of immunotherapy options may be useful for communi-
cating with people with multiple sclerosis (PwMS).
To correctly interpret study results, patients need
to understand that study findings are effect estimates
generated in a limited sample, which is assumed to
represent the total population [2]. CI provide infor-
mation about how accurate estimates are and thus
add important information about the uncertainty of
point estimates [3]. Understanding the relevance of CI
in addition to basic event rates and absolute risk re-
ductions may support patients and clinicians when
evaluating study results and making informed choices
[3]. The current Cochrane Handbook recommends to
communicate both relative and absolute measures of
risk and CI, which should be displayed in a ‘Summary
of findings’ table [4]. However, approaches to explain
CI to patients and consumers are rare [5] and no sys-
tematic evaluation exists.
For PwMS informed decision-making on disease-
modifying drugs is highly relevant for self-managing
their lives with this chronic progressive disease. PwMS
are confronted with different choices concerning
disease-modifying drugs, which are only partially effect-
ive but also bear relevant risks [6]. Adherence rates to
disease-modifying drugs are as low as 30 % [7] indicating
deficits also in the decision-making process. Communi-
cating uncertainties may be an important step towards a
better patient-medical-professional communication to
achieve informed choices to which patients adhere to.
Recent work has shown that addressing uncertainties
does not induce anxiety and fear, but increases involve-
ment and even adherence to disease-modifying drugs in
MS [8]. In order to make informed medical decisions,
PwMS not only need information about treatment
effects in numbers, such as absolute risk reductions, but
also information on the certainty of these estimates from
clinical studies.
Therefore, this study aims to develop and pilot-test
patient information (PI) materials to explain CI to
PwMS. As currently no validated questionnaire asses-
sing knowledge on CI is available, we aimed to de-
velop and pilot-test a multiple-choice questionnaire to
assess comprehension of CI.
Methods
Study design
Different PI materials were developed and pilot-tested
according to the Medical Research Council’s frame-
work for developing and evaluating complex interven-
tions [9].
Development
A systematic literature search was performed to identify
studies evaluating approaches to explain CI. In total
three different versions of PI materials were developed
to explain CI to PwMS. The recommendations concern-
ing the construction of evidence-based PI were consid-
ered [10, 11]. Different approaches were applied to
explain CI; using the illustrative example of an apple
farmer in two PI versions.
Feasibility/piloting
Assessment of feasibility included testing acceptability
of PI materials and exploring to what extent the PI
was judged suitable and attractive [12]. Practicability
of the PI was tested by assessing the time needed to
process the information, composition of text and
graphic illustration as well as understandability. Feasi-
bility of PI was tested in two consecutive stages. In a
pre-test phase, three different PI versions were tested
with non-academic staff members from the MS day
hospital in Hamburg and a consumer representative
from a self-help initiative. In a subsequent pilot-test
phase, the three PI versions were piloted with a sam-
ple of PwMS. The multiple-choice questionnaire was
tested with pilot-test phase participants [12]. Finally,
in a pilot-RCT, one PI (average weight version, see
below for details) was piloted together with the ques-
tionnaire in 64 PwMS (see Fig. 1).
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Participants
Pre-test and pilot-test phase
A convenience sample was used in the pre-test phase. In
total three female staff members of the MS day clinic
and one female consumer representative participated in
the study.
In the pilot-test phase, a purposeful sampling strategy
was applied to cover different distinct characteristics. In
total 21 PwMS aged 18 years or older were selected from
the MS day hospital, of whom eight declined to take part
in the study due to timing issues. In total six of 13
PwMS received ≥ 12 years of education and thereof access
to higher education Germany. Disease durations varied
from 1 month to 19 years. Seven participants (54 %) were
female. One patient dropped out at the beginning of the
interview, because she expected a different input. There-
fore, the final sample consisted of 12 PwMS.
Pilot RCT
Participants were recruited using mailing-lists of the MS
day hospital, the local MS self-help society and other
self-help initiatives [13–16].
After assessing the web-survey platform, participants
were informed about the study and asked to provide
demographic and disease specific data [17] and answer
five questions on numeracy [18]. Participants were ex-
cluded with a notification by the system in case they
filled in to be less than 18 years old or that they are not
diagnosed with MS. After that, they were randomly allo-
cated, using the UNIPARK randomisation sequence, to re-
ceive either the newly developed information or standard
information. Directly after the intervention, they were
asked to fill in the multiple-choice questionnaire.
Setting and procedure
A think-aloud approach combined with semi-structured
interviews was used to evaluate the PI and the question-
naire [19]. Participants (4 (staff members/consumer repre-
sentative) and 12 (PwMS)) were asked to read the PI via a
computer screen and verbalise their thoughts afterwards
[19]. The teach-back method was employed to allow fur-
ther improvement and clarification of the PI [20, 21].
All interviews, except one pre-test interview (tele-
phone-interview), were held face-to-face and were
audio-recorded at the MS day hospital by FF. There was
no professional relationship between interviewer and
participants. Interviews were not interrupted and re-
cordings were of very good audio quality. Interviews
ranged from 30 to 70 min.
The multiple-choice questionnaire with closed ques-
tions was developed following the recommendations by
Haladyna et al. [22] and evaluated in the pilot-test phase
and in the pilot-RCT. The average weight version on CI
was tested against standard information on CI based on
a formerly developed decision aid for PwMS [23] using
the online survey software UNIPARK [24]. The average
weight version, where a farmer wants to estimate the
average weight of his apples, was chosen because this
version was preferred by PwMS and contains all infor-
mation considered to be important to understand confi-
dence intervals (see 3.2.3 for details). The minimum
sample size was set to 60 people, assuming that this
Fig. 1 Study Flow
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would allow gaining sufficient information for the planned
evaluation of the questionnaire and the PI in a larger sam-
ple. It was not aimed to reach a statistical significant dif-
ference between the two groups, yet to use the results
after successfully piloting for the sample size calculation
of a future RCT to evaluate the PI in a larger sample.
Data analysis
Feasibility and pilot-phase
Interview recordings were transcribed using consistent
rules [25] and transcripts were content analysed using
Burnard’s approach [26]. The coding tree (Additional file
1) was developed along the gathered data and the struc-
ture of the interview guides. All transcripts were ana-
lysed using MAXQDA (version 11) and reviewed by a
second person (AR).
Pilot-RCT
Data analysis was performed using the SPSS (version
21). Demographic data were analysed using descriptive
statistics. An item analysis considering difficulty, distri-
bution and discriminatory power was performed on the
6-items on CI comprehension [27]. Cronbach’s alpha
(Kuder-Richardson) was calculated to determine internal
consistency. Discriminant validity was assessed compar-
ing the results to the abbreviated numeracy scale [18].
The questionnaire was complemented by four questions
(Likert scale from 1–10) to evaluate an overall subjective
rating of the understandability of the PI, the relevance of
the topic, subjective knowledge and estimated subjective
benefit of the PI.
Results
Systematic literature search
No study that explained CI to laypeople was identified
(see Additional file 2 for detailed information).
Feasibility and pilot-phase (written information)
Written patient information versions
A figure to display CI (Fig. 2) had been developed for an
information platform on MS as part of the DECIMS
(Decision Coaching in MS) project [28]. In the figure
both the absolute risk reduction and CI are presented.
We decided to explain CI using a non-medical ex-
ample followed by an MS specific example and devel-
oped three different PI on CI:
1) the average weight version
2) the worm prophylaxis version and
3) the short version.
Each version consists of an introduction, a main and a
final part, with only the main part differing between ver-
sions. The introduction starts with a question from a
virtual patient and is supposed to give participants an
idea in which context and why CI are used. For the main
part three versions were developed to cover different
levels of complexity and different approaches to explain
CI. The final part aims to transfer the gathered know-
ledge about CI to MS specific medications. While in the
short version, CI are explained as briefly as possible
without using an example, in the average weight and
worm prophylaxis versions the story of an apple farmer
is used to explain CI. In the average weight version, the
farmer wants to estimate the average weight of his ap-
ples and CI are illustrated using small and large random
samples of apples to estimate the average weight. In con-
trast, in the worm prophylaxis version, the farmer wants
to test whether an anti-worm treatment is effective to
prevent his apples from worm infestation. At first he
tries to treat a small sample of apples, then a larger one,
while he compares the results to untreated apples.
Pre-Test phase written patient information
During the pre-test the PI versions were revised before
they were shown to the next participant. Significant
changes were made in order to clarify contents. The nar-
rative line was optimised and sentences were shortened. A
statistician was introduced as a second virtual character,
apart from the farmer, to better structure the information.
Pilot-test phase written patient information
For the pilot-test interviews, participants were first shown
the average weight version, followed by the short and the
worm prophylaxis version. We chose to present the short
version between the other two versions to allow partici-
pants to rest between the two longer and more complex
versions. In general, participants’ reactions ranged from
positively interested on the one end, to being over-
whelmed on the other (interview no. 8 and 11). In total
four PwMS (interview no. 3, 5, 8 and 12) did comment on
the need of explaining CI to patients. It was considered as
important and PwMS wanted to read more about it, but
there were also contrary voices (interview no. 5). Please
see Additional file 3 for example quotes.
Understandability
In total five PwMS (interview no. 1, 3, 6, 8, and 10)
stated that the information on CI was easy to under-
stand and one person that it was well described (inter-
view no. 9). Other points, raised by one PwMS
respectively, were: too many pages with same content
making it difficult to stay attentive (interview no. 9); the
information was partly confusing, a lot at once and some
parts had to be read more than once (interview no. 11);
and that some sections need shorter sentences to be bet-
ter understood (interview no.10). No PwMS expressed
that the content was not understandable.
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In general, the presentation of numbers was described
as a burden by four PwMS (interview no. 4, 5, 9 and 10).
One PwMS reported that he found it difficult to tell
whether numbers were derived from calculations of real
figures or were made up as an example (interview no. 8).
Two PwMS also stated that their numerical skills and
their competencies in mathematics were weak (interview
no. 4 and 8). On the contrary, another PwMS pointed out
to remember the content visually presented, but later
stressed to have problems with numbers (interview no. 9).
Different versions and comparison of the different
versions
In total six PwMS were positive about the apple farmer
approach (interview no. 1, 3, 6, 8, 10 and 12). While five
PwMS clearly expressed that they preferred the average
weight version; three PwMS liked the worm prophylaxis
version better and one PwMS liked the short version
most. Another PwMS stated that he could not choose
one, because every version yielded different information
and only all three versions combined gave a complete
picture of CI. Information about the favourite version
was missing for two PwMS.
Confidence intervals and multiple sclerosis specific
medications
PwMS did not comment much on the final part of the
PI. Two PwMS were pleased about the transfer to MS
and MS medications (interview no. 4 and 8). Despite the
dense and relatively difficult text, negative comments
were rare (two persons, interview no. 5 and 6).
Comprehension of confidence intervals
The comprehension of CI was mostly assessed by
the teach-back phase and the multiple choice ques-
tionnaire. Questionnaire results are presented in sec-
tion 3.3.
Teach back
All PwMS of the pilot-test phase were asked to teach
back the following aspects: definition of CI, benefits
of using CI, width of CI, statistical significance and
the apple farmer’s approach to answer his question
(e.g. to estimate the average weight of his apples).
Overall, it was difficult for the PwMS to teach-back
the content. However, some PwMS were able to teach-
back the content quite well, whereas others could not
teach-back the content predominantly correct. Some
PwMS were able to teach-back the content of some
parts while they had problems with other parts (see
Additional file 4: Table S1).
Development and pilot-testing of the multiple choice
questionnaire
The developed questionnaire initially consisted of eight
multiple choice questions, of which four were visually
illustrated. The questions addressed:
– the definition of CI
Fig. 2 Confidence intervals (drug therapy effects in relapsing-remitting MS), Number of patients without relapses for 2 years due to drug therapy.
References [30, 31, 35–39, 40–43]
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– the interpretation of CI and of point estimates based
on an example
– the meaning of the width of CI and of the zero-line
– the interpretation of CI as well as influencing factors.
The questionnaire was pilot-tested with six of the 12
PwMS. Five of eight questions were answered correctly
by five or more PwMS (see Additional file 4: Table S2).
Further development of the multiple choice questionnaire
According to the feed-back of the PwMS, the ques-
tionnaire was further adapted. Two questions were
deleted, as they addressed for the same content as
other questions and wording of some questions was
changed. The revised questionnaire was assessed again
by four PwMS (see Additional file 5). No further need
for revision was revealed.
Pilot randomised controlled trial
About 1000 persons were invited to take part via the
mailing-lists. Participating PwMS were randomised to re-
ceive either the average weight version (IG) or standard
information (CG). The survey was started by 115 PwMS,
with 64 finishing the survey (36 IG/ 28 CG) (see Fig. 3).
Baseline demographics and disease specific data informa-
tion are presented in Table 1. There were significantly more
female PwMS in the CG. Otherwise there were no statisti-
cally significant differences in demographic parameters.
PwMS in the IG answered 4.8 (mean, SD 1.3) of six
questions correctly, while PwMS in the CG answered 3.8
(SD 1.2) questions correctly (mean difference 1.1 (95 %
CI 0.42–1.69), p = 0.002, two-tailed t-test).
The questionnaire was developed to assess knowledge
on CI in the context of study results on treatment op-
tions. As there was no comparative instrument available,
Fig. 3 Flow diagram pilot RCT (CONSORT 2010) [44]





Age (mean) 47.3 43.8
Females 19 (53 %) 22 (79 %)*
Education (highest degree)
Secondary school 15 (41.7 %) 16 (57.1 %)
Academic degree 21 (58.3 %) 12 (42.9 %)
Disease course**
CIS 0 2 (7.4 %)
RRMS 22 (61.1 %) 20 (71.4)
SPMS 9 (25 %) 4 (14.3 %)
PPMS 0 2 (7.1 %)
Other 3 (8.3 %) 0
Disease duration (mean) 9.1 years 9.5 years
Currently on Immunotherapy 18 (50 %) 11 (39.3 %)
PDDS (mean) 2.86 2.04
IG intervention group, CG control group, CIS clinically isolated syndrome, RRMS
relapsing remitting multiple sclerosis, SPMS secondary progressive multiple
sclerosis, PPMS primary progressive multiple sclerosis, PDDS patient
determined disease steps *Statistical significant difference (p = 0,039),
**Missing data for two participants in the IG
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the two groups were analysed separately concerning diffi-
culty, internal consistency and discriminatory power [27].
The difficulty of the six items ranged between 0.43
and 0.94 in the IG and between 0.36 and 0.86 in the
CG (Table 2).
Cronbach’s alpha was 0.57 in the IG and 0.21 in the
CG. Discriminatory power ranged between 0.17 and 0.45
in the IG and between 0.15 and 0.28 in the CG.
Due to a software error, only two of five questions on
numeracy could be analysed. There was no significant
correlation between numeracy and questionnaire results
for the whole sample (0.161, p = 0.21). Numeracy in the
CG correlated (Pearson’s r) positively (0.473, p = 0.01)
with the mean sum score of the questionnaire, but not
in the IG (-0.06, p = 0.7).
Concerning the general evaluation questions, the average
weight version received better results. Results concerning
understandability, subjective knowledge and benefits of the
PI significantly favoured the IG (p = 0.01) (Table 3).
Discussion and conclusion
Discussion
To our knowledge this is the first study to explain CI to
patients. We developed and pre-tested three different PI
versions on CI and piloted them successfully following
the Medical Research Council’s guidance for developing
and evaluating complex interventions [9]. Our pilot data
indicate that CI can be made understandable through
adequate PI interventions. PwMS contributed valuably
to improve readability as well as understandability and
enhanced comprehension. The majority of PwMS pre-
ferred either the average weight version or the worm
prophylaxis version. The worm prophylaxis version was
more difficult, but mirrored the setting of clinical trials
very well, because of the treatment example. Therefore,
this example could ease the transfer to immunotherapy
decision making, as emphasised by some PwMS.
Statistical illiteracy by physicians and patients can re-
sult in misunderstanding study results, especially of
numbers and verbal frequency statements [10, 29]. CI
are beneficial for judging on the clinical relevance of
statistical reporting and to reduce the chance of results
being misinterpreted [3], because point estimates are
complemented. Therefore, our graphical PI on CI, dis-
playing both absolute risk reduction and significance of
results, may be a step forward in patient education. The
communication of CI could help to judge on the validity
of the estimate by giving additional information to sim-
ply reporting point estimates. For example, the CI for
the absolute risk reduction of glatiramer acetate (Copax-
one®) concerning disability over 2 years ranges from zero
to 21 and can be compared to other treatment options
[30, 31]. However, not every patient needs to process
and understand point estimates and CI as roles within
decision making process have to be clarified [32] and
thus might lead to a physician-led decision. Nonetheless,
comprehensive information has to be made accessible in
order to allow patients to get involved as much as they
want based on the bioethical principle of autonomy [33].
Therefore, medical management should always strive for
the highest possible degree of patient autonomy. This
study is embedded in an ongoing project, in which a
nurse-led decision-coaching intervention is evaluated to
enable PwMS to make informed treatment choices [28].
The patient information will be made accessible on the
online information platform after its evaluation in an
RCT [34].
Limitations of this study
There are some shortcomings of this study. PwMS of
this pilot-study had the advantage of comparing all three
versions with each other. The teach-back of the content
indicated that some PwMS benefited from going through
more than one version as they could teach back more
Table 2 Item difficulty and discriminatory power
Item 1 Item 2 Item 3 Item 4 Item 5 Item 6
Mean item difficulty (SD)
IG (N = 36) 0.94 (0.23) 0.80 (0.40) 0.75 (0.44) 0.43 (0.51) 0.86 (0.35) 0.92 (0.28)
CG (N = 36) 0.68 (0.48) 0.86 (0.36) 0.54 (0.51) 0.36 (0.49) 0.5 (0.51) 0.82 (0.39)
Discriminatory power
IG (N = 36) 0.17 0.33 0.41 0.45 0.27 0.23
CG (N = 36) - 0.15 - 0.04 0.28 0.23 0.10 0.14
IG intervention group, CG control group







Subjective knowledge 6.6 4.8
Benefit of the PI 7.8 6.0
Understandability of the PI (1 = not understandable at all – 10 = very good to
understand), Relevance of the topic CI (1 = not relevant at all – 10 = very
relevant), Subjective knowledge on CI (1 = not understood at all – 10 = fully
understood), Benefit of a PI on CI (1 = not helpful at all – 10 = very helpful)
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information correctly after they had read the average
weight and worm prophylaxis version. However, as the
average weight version was always seen first by PwMS,
the results might differ to another possible order. To ac-
count for this in a future RCT to evaluate all PI versions
in larger sample [34], PwMS can watch a second video
after having answered the questions. Due to the length
and dense of information and drop-out rates it is not
scheduled that PwMS see more than one PI material.
Caused by the small sample, the percentage of females
in our pilot trial was imbalanced between the groups.
However, we do not believe that this effected study re-
sults. Nevertheless, we will investigate on the impact of
sex on the outcomes in the larger study.
Internal consistency and discriminatory power of the
questionnaire were lower than aimed. For a high internal
consistency, Cronbach’s alpha should have been over 0.70
and discriminatory power should have ranged between
0.40 and 0.70 [27], which was not reached for any ques-
tion in the CG, whereas it was reached in two out of six
questions in the IG. However, because the questionnaire
consists of six questions only aiming to evaluate disease
specific knowledge and comprehension on confidence in-
tervals in general, high internal consistency would have
been difficult to reach. Higher Cronbach’s alpha level in
the IG indicates that gained knowledge leads to more con-
sistent replies. The lack of a correlation of correct answers
with numeracy in the IG might be due to the fact that a
high score in numeracy is not necessarily helpful to under-
stand the topic. However, this needs further evaluation.
With a mean difference of one question between
groups clinical and practical relevance is an open ques-
tion. Nevertheless, with more than two thirds of the
questionnaire answered correctly by the IG it could be
assumed that this kind of information on treatment op-
tions is understandable for PwMS. However, results need
to be confirmed in a larger sample. Further, other pres-
entation formats as for example videos might be a more
attractive format for the user to receive information on
CI than written information.
Finally, recruitment for the pilot-RCT was conducted
via mailing-lists of the MS day hospital and self-help ini-
tiatives. Therefore, only PwMS, who are potentially
interested in being updated by those institutions, were
reached. Being aware that not all people read the news-
letter, to us the response rate with 64 replies out of 115
who did login into the survey seemed sufficient for a
pilot study and our recruitment target of 60 PwMS was
fulfilled. However, a large study with a less biased sample
is needed to evaluate the PI on CI.
Conclusion
The pilot-phase shows promising results concerning ac-
ceptability and feasibility of different information materials
on CI. PwMS may benefit from understanding CI, because
they will be able to better compare different therapy
options.
Understanding CI and other numerical data is of high
importance for an informed treatment decision making
process. Therefore, further research should focus on
possibilities to explain numerical data of different for-
mats in different patient groups.
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